10-KPeriod: FY2000

BOSTON SCIENTIFIC CORP Annual Report, Year Ended Dec 31, 2000

Filed April 2, 2001For Securities:BSX

Summary

Boston Scientific Corporation's 2000 10-K report highlights a company deeply invested in the development, manufacturing, and marketing of less invasive medical devices. The company's strategy centers on product diversity, continuous innovation, operational excellence, focused marketing, and an expanding international presence. In 2000, international sales constituted a significant 41% of total net sales, underscoring the global reach of its operations. The company's product portfolio spans a broad range of interventional medical specialties, including cardiology, electrophysiology, gastroenterology, and neuro-endovascular therapy. Growth has been historically driven by strategic acquisitions and alliances, and the company has several strategic initiatives and acquisitions planned or completed in early 2001, indicating an ongoing commitment to expanding its market share and technological capabilities. The report also details significant investments in research and development, with approximately $199 million spent in 2000, representing about 7% of net sales, to fuel future innovation.

Key Highlights

  • 1Boston Scientific is a global developer, manufacturer, and marketer of less invasive medical devices, with a broad product line across numerous interventional specialties.
  • 2International sales represented a substantial 41% of net sales in 2000, indicating a strong global market presence.
  • 3The company's growth strategy relies heavily on product diversity, innovation through R&D ($199 million in 2000), operational efficiency, focused marketing divisions, and strategic acquisitions/alliances.
  • 4Significant early 2001 strategic initiatives include acquisitions of Interventional Therapeutics, Inc. (IVT), Embolic Protection, Inc., Quanam Medical Corporation, and Catheter Innovations, Inc., aiming to expand its product offerings and technological capabilities.
  • 5The company faces significant competition from major players like Medtronic, Johnson & Johnson, and Guidant Corporation, competing on factors including safety, efficacy, ease of use, and increasingly, price.
  • 6Boston Scientific has a robust patent portfolio with over 1,900 US patents and more than 3,500 pending applications worldwide, but also faces ongoing patent litigation.
  • 7A worldwide operations plan was initiated in 2000 to increase productivity and enhance innovation by optimizing the supply chain, manufacturing processes, and consolidating plant operations.

Frequently Asked Questions

Boston Scientific develops, manufactures, and markets less invasive medical devices used in a wide array of interventional medical specialties, including interventional cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, pulmonary medicine, interventional radiology, oncology, urology, and vascular surgery. Their products aim to offer alternatives to traditional surgery by reducing risk, trauma, cost, and procedure time.

International operations are a key component of Boston Scientific's growth strategy. In the fiscal year 2000, international sales accounted for approximately 41% of the Company's net sales. They operate international manufacturing facilities in Ireland and have direct marketing and sales operations in 40 countries, leveraging these to increase market share and access global technological developments.

The company's core strategy involves continuous product innovation, expanding its diverse product line, enhancing operational excellence through supply chain optimization and manufacturing efficiencies, maintaining focused marketing efforts through specialized divisions, and growing its international presence. Strategic acquisitions and alliances are also crucial for complementing existing product lines and enhancing technological capabilities.

Key risks and challenges include intense competition from established medical device companies, the complex and time-consuming regulatory approval process for medical devices (FDA and international agencies), potential product liability claims, patent litigation and intellectual property protection, fluctuations in foreign currency exchange rates affecting international operations, and increasing pressure on pricing due to managed care and consolidated healthcare providers.